This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa
Patients diagnosed with symptomatic mild to moderate P. falciparum malaria with a parasite density of >= 5000 parasites/μl
Adult male, age 18-55 years old or adult female, age 18-55 years that are post-menopausal, or test negative on a pregnancy test and will be on active birth control through to the end of the follow up period.
Provision of informed consent and agrees to hospital admission for 48-72hrs
Good health condition other than malaria
Prospective study participant, LAR and/or impartial witness (where applicable) declines to provide informed consent.
significant confusion or impaired consciousness (including unarousable coma)
multiple convulsions (more than two episodes within 24 hours),
respiratory distress
Victoria Biomedical Research Institute
Lead sponsor
Purdue University
Collaborator